DelveInsight’s “Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cytokine Release Syndrome, historical and forecasted epidemiology as well as the Cytokine Release Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Cytokine Release Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Cytokine Release Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cytokine Release Syndrome Market Insights
Cytokine Release Syndrome Overview
Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation. Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neuropsychiatric syndrome that can occur in some patients who are treated with immunotherapy and may or may not accompany CRS.
Some of the key facts of the Cytokine Release Syndrome Market Report:
- The Cytokine Release Syndrome market size was valued at USD 4.3 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The highest number of cases of Cytokine Release Syndrome developed CAR-T cell therapy were recorded in the United States. Epidemiological analysis by DelveInsight shows that there were nearly 2,896 cases of Cytokine Release Syndrome in the United States in the year 2021
- More than 1,000 cases of Cytokine Release Syndrome developed after the CAR-T cell therapies were recorded in the European region in 2021
- In the United States, 3,774 cases of hematologic malignancies received CAR-T therapies in the year 2021.These malignancies included ALL, B-Cell NHL (DLBCL, FL, PMBCL etc.) & Multiple Myeloma
- The number of patients who develop Cytokine Release Syndrome following CART therapies in the 7MM were approximately 4,156 in 2021
- Key Cytokine Release Syndrome Companies: Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, and others
- Key Cytokine Release Syndrome Therapies: Itacitinib, Anakinra & Axicabtagene Ciloleucel, Defibrotide, and others
Get a Free sample for the Cytokine Release Syndrome Market Report –
https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market
Key benefits of the Cytokine Release Syndrome Market report:
- Cytokine Release Syndrome market report covers a descriptive overview and comprehensive insight of the Cytokine Release Syndrome Epidemiology and Cytokine Release Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Cytokine Release Syndrome market report provides insights on the current and emerging therapies.
- Cytokine Release Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Cytokine Release Syndrome market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Cytokine Release Syndrome market.
Download the report to understand which factors are driving Cytokine Release Syndrome epidemiology trends @ Cytokine Release Syndrome Epidemiological Insights
Cytokine Release Syndrome Market
The dynamics of the Cytokine Release Syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“As immunotherapies become translated into the clinical setting, a balance between efficacy and toxicity management must be achieved. Tremendous efforts have been put forward to use synthetic engineering of T-cells, including SUPRA CAR T-cells, synNotch receptors, and CRISP Rediting to enhance efficacy and off-the-shelf product feasibility.”
Cytokine Release Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Cytokine Release Syndrome Epidemiology Segmentation:
The Cytokine Release Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Cytokine Release Syndrome
- Prevalent Cases of Cytokine Release Syndrome by severity
- Gender-specific Prevalence of Cytokine Release Syndrome
- Diagnosed Cases of Episodic and Chronic Cytokine Release Syndrome
Cytokine Release Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cytokine Release Syndrome market or expected to get launched during the study period. The analysis covers Cytokine Release Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cytokine Release Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Cytokine Release Syndrome market share @ Cytokine Release Syndrome market forecast
Cytokine Release Syndrome Therapies and Key Companies
- Itacitinib: Incyte
- Anakinra & Axicabtagene Ciloleucel: Kite, A Gilead Company
- Defibrotide: Jazz Pharmaceuticals
Cytokine Release Syndrome Market Drivers
- Increasing incidence of Acute cytokine release syndrome (CRS)
- Increasing R&D activities
- Non-competitive landscape
Scope of the Cytokine Release Syndrome Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Cytokine Release Syndrome Companies: Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, and others
- Key Cytokine Release Syndrome Therapies: Itacitinib, Anakinra & Axicabtagene Ciloleucel, Defibrotide, and others
- Cytokine Release Syndrome Therapeutic Assessment: Cytokine Release Syndrome current marketed and Cytokine Release Syndrome emerging therapies
- Cytokine Release Syndrome Market Dynamics: Cytokine Release Syndrome market drivers and Cytokine Release Syndrome market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Cytokine Release Syndrome Unmet Needs, KOL’s views, Analyst’s views, Cytokine Release Syndrome Market Access and Reimbursement
Cytokine Release Syndrome Market Barriers
- Lack of awareness about the disease
- Lack of disease understanding
- Misdiagnosis of Cytokine Release Syndrome
Table of Contents
1. Cytokine Release Syndrome Market Report Introduction
2. Executive Summary for Cytokine Release Syndrome
3. SWOT analysis of Cytokine Release Syndrome
4. Cytokine Release Syndrome Patient Share (%) Overview at a Glance
5. Cytokine Release Syndrome Market Overview at a Glance
6. Cytokine Release Syndrome Disease Background and Overview
7. Cytokine Release Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Cytokine Release Syndrome
9. Cytokine Release Syndrome Current Treatment and Medical Practices
10. Cytokine Release Syndrome Unmet Needs
11. Cytokine Release Syndrome Emerging Therapies
12. Cytokine Release Syndrome Market Outlook
13. Country-Wise Cytokine Release Syndrome Market Analysis (2019–2032)
14. Cytokine Release Syndrome Market Access and Reimbursement of Therapies
15. Cytokine Release Syndrome Market Drivers
16. Cytokine Release Syndrome Market Barriers
17. Cytokine Release Syndrome Appendix
18. Cytokine Release Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Cytokine Release Syndrome treatment, visit @ Cytokine Release Syndrome Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/